AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacyOct 30Weekly roundup, 8 itemsalbuterol sulfate and budesonideAstraZenecaUpdated
FDA grants accelerated approval to Ultomiris for IgA nephropathyOct 22Regulatory decisionAstraZenecaravulizumab
CHMP backs two AstraZeneca drugs: Klygefa in gMG, Enhertu in early breast cancerSep 21Regulatory milestoneAstraZenecafam-trastuzumab deruxtecan-nxki
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819
Xencor to receive $105 million from Alexion to settle Ultomiris royalty disputeJul 29Quarterly updateravulizumabXencor, Inc.
AstraZeneca's Ultomiris misses main goal in adult HSCT-TMA trialJul 27Clinical readoutAstraZenecaravulizumab